Infusion Therapy Articles & Analysis

Vascular access technology pioneer Velano Vascular today revealed that the 2021 Infusion Therapy Standards of Practice, 8th Ed., include its needle free PIVO™ device and evidence of the procedure’s improved performance for inpatient blood draws. Updated every five years and considered the preeminent guidance for infusion therapy, the newly reset standards from the Infusion Nurses ...

By Velano Vascular

Following the announced closing of the acquisition of Ivenix and its advanced infusion pump technology, Fresenius Kabi now offers healthcare professionals a broad and expanding portfolio of advanced infusion pumps and solutions to meet health care needs across the continuum of care. Fresenius Kabi is the leading provider of IV pumps and solutions in Europe. The company is now investing to ...

By Ivenix, Inc.

Christie® Medical Holdings, Inc., with its market-leading vein finder technology, VeinViewer® system, today announced an alliance with B. Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. Many ...

By Christie Medical Holdings, Inc.

Inspiration Healthcare Group plc is pleased to announce the opening of its new corporate head office in the Manor Royal Business District, Crawley, UK. The newly redeveloped 4,500 ft2 office in the Satellite Business Village was officially opened on Friday 3rd March 2017 by Henry Smith MP who unveiled a commemorative plaque and joined guests, the Inspiration Healthcare Group plc Board of ...

By Inspiration Healthcare Group plc

Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and ...

By Atomwise Inc.

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update. “After a busy 2021 with new patients dosed across three clinical trials, we acted in early January to strategically position AVROBIO ...

By Tectonic Therapeutic, Inc.

Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...

By Immunai

WALNUT CREEK, Calif., June 2, 2021 /PRNewswire/ -- Oncodisc Inc. ("Oncodisc") today announced that it was acquired by Veris Health Inc ("Veris"), a majority owned digital health subsidiary of PAVmed Inc. ("PAVmed"). Oncodisc, a digital health company with groundbreaking tools to improve personalized cancer care through remote patient monitoring, was founded by experienced ...

By Oncodisc

Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Flowonix Maestro™ Software for Clinician Programmers used to program Prometra® Pump Systems. The new software is designed to improve the user experience for both clinicians and patients. Flowonix expects to begin introducing the new software to customers and implementing the ...

By Flowonix Medical Inc.

Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022 Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter ...

By Forge Biologics, Inc.

Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. "The study ...

By Flowonix Medical Inc.

Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a micro-infusion device that tightly ...

By Flowonix Medical Inc.